Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

A straightforward and atom-economical method for the synthesis of quinolines and pyrroles has been reported. Using Earth-abundant, commercially available CrCl salt as a catalyst and the inexpensive, bench-stable 6,6'-dimethyl-2,2'-dipyridyl as a ligand, this chromium-catalyzed acceptorless dehydrogenative coupling provides important heterocycles, quinolines and pyrroles, in synthetically useful yields with good functional group tolerance, releasing water and hydrogen gas as by-products. Notably, the described protocol was also found to be applicable to the sustainable synthesis of highly substituted fused polycyclic quinolines and pyrroles. Moreover, the synthetic value of this operationally simple protocol was demonstrated by gram-scale synthesis of quinolines.

Download full-text PDF

Source
http://dx.doi.org/10.1039/d5ob00150aDOI Listing

Publication Analysis

Top Keywords

quinolines pyrroles
16
synthesis quinolines
12
sustainable synthesis
8
chromium-catalyzed acceptorless
8
acceptorless dehydrogenative
8
dehydrogenative coupling
8
quinolines
5
pyrroles
4
pyrroles enabled
4
enabled chromium-catalyzed
4

Similar Publications

First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial.

Lancet Oncol

September 2025

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address:

Background: The underexplored potential of PD-L1 blockade in advanced renal cell carcinoma highlights an urgent need for novel agents. This trial aimed to compare benmelstobart (a novel PD-L1 inhibitor) plus anlotinib with sunitinib as first-line treatment for advanced renal cell carcinoma.

Methods: ETER100 was a multicentre, randomised, open-label, phase 3 trial conducted at 37 medical sites in China.

View Article and Find Full Text PDF

Multi-Component Synthesis of New Fluorinated-Pyrrolo[3,4-]pyridin-5-ones Containing the 4-Amino-7-chloroquinoline Moiety and In Vitro-In Silico Studies Against Human SARS-CoV-2.

Int J Mol Sci

August 2025

Departamento de Química, Universidad Autónoma Metropolitana-Iztapalapa, Av. Ferrocarril San Rafael Atlixco 186, Col. Leyes de Reforma 1A Sección, Iztapalapa, Ciudad de México C.P. 09310, Mexico.

A one-pot synthetic methodology that combines an Ugi-Zhu three-component reaction (UZ-3CR) with a cascade sequence (intermolecular Diels-Alder cycloaddition/intramolecular -acylation/decarboxylation/dehydration) using microwave-heating conditions, ytterbium (III) triflate (Yb(OTf)) as the catalyst, and chlorobenzene (for the first time in a multi-component reaction (MCR)) as the solvent, was developed to synthesize twelve new fluorinated-pyrrolo[3,4-]pyridin-5-ones containing a 4-amino-7-chloroquinoline moiety, yielding 50-77% in 95 min per product, with associated atom economies around 88%, also per product. Additionally, by in vitro tests, compounds and were found to effectively stop early SARS-CoV-2 replication, IC = 6.74 µM and 5.

View Article and Find Full Text PDF

Hydrothermal carbonization (HTC) is an energy-efficient and environmentally friendly method for treating waste activated sludge (WAS). However, the aqueous phase by-product (carbonization liquid, CL) presents a significant challenge because of its high nitrogen content and complex organic composition, which remains inadequately explored. This study uses non-targeted screening and mass-difference analysis to research organic nitrogen compounds (Org-Ns) in CL.

View Article and Find Full Text PDF

I would like to welcome you to the August issue of Rhinology. In the latest issue of Rhinology, you will find high quality articles spanning the entire breadth of the field of rhinology. From studies on inflammatory sinus disease to skull base pathology, from medical to surgical treatments, every reader is sure to find studies of interest and applicability to their practice.

View Article and Find Full Text PDF

Human dihydroorotate dehydrogenase (hDHODH) represents an attractive target for the treatment of cancer, diabetes, anti-infective and autoimmune diseases. In drug development, hDHODH inhibitors with great potency, good chemical stability and low toxicity open the broad therapeutic perspectives. Accordingly, this study identified the first bioconjugates as highly effective compounds in inhibition of hDHODH.

View Article and Find Full Text PDF